Literature DB >> 34352659

Reliability of a computational platform as a surrogate for manually interpreted immunohistochemical markers in breast tumor tissue microarrays.

Michelle R Roberts1, Gabrielle M Baker2, Yujing J Heng2, Michael E Pyle2, Kristina Astone3, Bernard A Rosner4, Laura C Collins2, A Heather Eliassen5, Rulla M Tamimi6.   

Abstract

BACKGROUND: Pathologist and computational assessments have been used to evaluate immunohistochemistry (IHC) in epidemiologic studies. We compared Definiens Tissue Studio® to pathologist scores for 17 markers measured in breast tumor tissue microarrays (TMAs) [AR, CD20, CD4, CD8, CD163, EPRS, ER, FASN, H3K27, IGF1R, IR, Ki67, phospho-mTOR, PR, PTEN, RXR, and VDR].
METHODS: 5 914 Nurses' Health Study participants, diagnosed 1976-2006 (NHS) and 1989-2006 (NHS-II), were included. IHC was conducted by the Dana-Farber/Harvard Cancer Center Specialized Histopathology Laboratory. The percent of cells staining positive was assessed by breast pathologists. Definiens output was used to calculate a weighted average of percent of cells staining positive across TMA cores for each marker. Correlations between pathologist and computational scores were evaluated with Spearman correlation coefficients. Receiver-operator characteristic curves were constructed, using pathologist scores as comparison.
RESULTS: Spearman correlations between pathologist and Definiens assessments ranged from weak (RXR, rho=-0.05; CD163, rho = 0.10) to strong (Ki67, rho = 0.79; pmTOR, rho = 0.77). The area under the curve was >0.70 for all markers except RXR.
CONCLUSION: Our data indicate that computational assessments exhibit variable correlations with interpretations made by an expert pathologist, depending on the marker evaluated. This study provides evidence supporting the use of computational platforms for IHC evaluation in large-scale epidemiologic studies, with the caveat that pilot studies are necessary to investigate agreement with expert assessments. In sum, computational platforms may provide greater efficiency and facilitate high-throughput epidemiologic analyses.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Computational pathology; Epidemiology; Immunohistochemistry

Mesh:

Substances:

Year:  2021        PMID: 34352659      PMCID: PMC8887925          DOI: 10.1016/j.canep.2021.101999

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.890


  18 in total

1.  Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma.

Authors:  Annette Feuchtinger; Tabitha Stiehler; Uta Jütting; Goran Marjanovic; Birgit Luber; Rupert Langer; Axel Walch
Journal:  Histochem Cell Biol       Date:  2014-08-26       Impact factor: 4.304

Review 2.  Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment I.

Authors:  R A Walker
Journal:  Histopathology       Date:  2006-10       Impact factor: 5.087

3.  Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system.

Authors:  Martin Braun; Robert Kirsten; Niels J Rupp; Holger Moch; Falko Fend; Nicolas Wernert; Glen Kristiansen; Sven Perner
Journal:  Histol Histopathol       Date:  2013-01-30       Impact factor: 2.303

4.  Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods.

Authors:  Leslie K Diaz; Aysegul Sahin; Nour Sneige
Journal:  Ann Diagn Pathol       Date:  2004-02       Impact factor: 2.090

5.  Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies.

Authors:  Kelly L Bolton; Montserrat Garcia-Closas; Ruth M Pfeiffer; Máire A Duggan; William J Howat; Stephen M Hewitt; Xiaohong R Yang; Robert Cornelison; Sarah L Anzick; Paul Meltzer; Sean Davis; Petra Lenz; Jonine D Figueroa; Paul D P Pharoah; Mark E Sherman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

6.  Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer.

Authors:  Z M A Mohammed; D C McMillan; B Elsberger; J J Going; C Orange; E Mallon; J C Doughty; J Edwards
Journal:  Br J Cancer       Date:  2012-01-03       Impact factor: 7.640

7.  A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.

Authors:  Fangfang Zhong; Rui Bi; Baohua Yu; Fei Yang; Wentao Yang; Ruohong Shui
Journal:  PLoS One       Date:  2016-02-29       Impact factor: 3.240

8.  Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.

Authors:  Elton Rexhepaj; Donal J Brennan; Peter Holloway; Elaine W Kay; Amanda H McCann; Goran Landberg; Michael J Duffy; Karin Jirstrom; William M Gallagher
Journal:  Breast Cancer Res       Date:  2008-10-23       Impact factor: 6.466

9.  Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.

Authors:  William J Howat; Fiona M Blows; Elena Provenzano; Mark N Brook; Lorna Morris; Patrycja Gazinska; Nicola Johnson; Leigh-Anne McDuffus; Jodi Miller; Elinor J Sawyer; Sarah Pinder; Carolien H M van Deurzen; Louise Jones; Reijo Sironen; Daniel Visscher; Carlos Caldas; Frances Daley; Penny Coulson; Annegien Broeks; Joyce Sanders; Jelle Wesseling; Heli Nevanlinna; Rainer Fagerholm; Carl Blomqvist; Päivi Heikkilä; H Raza Ali; Sarah-Jane Dawson; Jonine Figueroa; Jolanta Lissowska; Louise Brinton; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Angela Cox; Ian W Brock; Simon S Cross; Malcolm W Reed; Fergus J Couch; Janet E Olson; Peter Devillee; Wilma E Mesker; Caroline M Seyaneve; Antoinette Hollestelle; Javier Benitez; Jose Ignacio Arias Perez; Primitiva Menéndez; Manjeet K Bolla; Douglas F Easton; Marjanka K Schmidt; Paul D Pharoah; Mark E Sherman; Montserrat García-Closas
Journal:  J Pathol Clin Res       Date:  2014-12-04

10.  High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium.

Authors:  Mustapha Abubakar; William J Howat; Frances Daley; Lila Zabaglo; Leigh-Anne McDuffus; Fiona Blows; Penny Coulson; H Raza Ali; Javier Benitez; Roger Milne; Herman Brenner; Christa Stegmaier; Arto Mannermaa; Jenny Chang-Claude; Anja Rudolph; Peter Sinn; Fergus J Couch; Rob A E M Tollenaar; Peter Devilee; Jonine Figueroa; Mark E Sherman; Jolanta Lissowska; Stephen Hewitt; Diana Eccles; Maartje J Hooning; Antoinette Hollestelle; John Wm Martens; Carolien Hm van Deurzen; Manjeet K Bolla; Qin Wang; Michael Jones; Minouk Schoemaker; Annegien Broeks; Flora E van Leeuwen; Laura Van't Veer; Anthony J Swerdlow; Nick Orr; Mitch Dowsett; Douglas Easton; Marjanka K Schmidt; Paul D Pharoah; Montserrat Garcia-Closas
Journal:  J Pathol Clin Res       Date:  2016-04-06
View more
  2 in total

1.  Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses' Health Studies.

Authors:  Rulla M Tamimi; A Heather Eliassen; Tengteng Wang; Yujing J Heng; Gabrielle M Baker; Vanessa C Bret-Mounet; Liza M Quintana; Lisa Frueh; Susan E Hankinson; Michelle D Holmes; Wendy Y Chen; Walter C Willett; Bernard Rosner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-10-04       Impact factor: 4.090

2.  Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications.

Authors:  Gabrielle M Baker; Vanessa C Bret-Mounet; Tengteng Wang; Mitko Veta; Hanqiao Zheng; Laura C Collins; A Heather Eliassen; Rulla M Tamimi; Yujing J Heng
Journal:  J Pathol Inform       Date:  2022-06-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.